Results 161 to 170 of about 49,130 (295)
Clinical and Genetic Characteristics of Hereditary Arrhythmias and Cardiomyopathies in the Middle East. [PDF]
Ahmad O +9 more
europepmc +1 more source
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Cardiac screening in the young for the detection of cardiovascular disease and prevention of sudden cardiac death. [PDF]
Tardo DT, Sharma S.
europepmc +1 more source
Inherited cardiomyopathies [PDF]
Miles, C, Fanton, Z, Tome, M, Behr, ER
openaire +3 more sources
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
Genetic Architecture of Pediatric Cardiomyopathies Assessed by Whole-Exome Sequencing: Insights Into Early-Onset and Syndromic Forms. [PDF]
Giovannangeli L +18 more
europepmc +1 more source
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli +17 more
wiley +1 more source
Cardiac Magnetic Resonance Radiomics for Diagnosis, Phenotyping and Risk Stratification of Cardiomyopathies. [PDF]
Granitto C +11 more
europepmc +1 more source
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
Immunological Reprogramming in Cardiomyopathies: From Cardiomyocyte Injury to Disease of the Cardiac Immune Ecosystem. [PDF]
Urbanowicz T, Filipiak KJ.
europepmc +1 more source

